Published in

Cervical cancer, 2022

DOI: 10.1136/ijgc-2022-esgo.111

Links

Tools

Export citation

Search in Google Scholar

2022-RA-1263-ESGO Phase II randomized BGOG-CX3 trial comparing atezolizumab in combination with doxorubicin versus doxorubicin alone in second-line or later recurrent cervical cancer

Proceedings article published in 2022 by Liselore Loverix, Rawand Salihi, Anne-Sophie van Rompuy, Adriaan Vanderstichele, Els van Nieuwenhuysen, Thaïs Baert, Philip Debruyne, Nathalie Cornez, Stéphanie Henry, Patrick Neven, Sileny Han, Patrick Berteloot, Siel Olbrecht, Tina Laga, Pieter Busschaert and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Question mark in circle
Preprint: policy unknown
Upload
Question mark in circle
Postprint: policy unknown
Upload
Question mark in circle
Published version: policy unknown
Upload